Table 1.

Clinical studies of agents targeting the VISTA checkpoint.

Intervention	MOA	Condition(s)	Study description	Enrolled (N)	Identifier	Sponsor	Location	Status
JNJ-61610588 (CI-8893)	Fully human IgG1ĸ Anti-VISTA mAb	Advanced cancers	An open-label, first-in-human Phase 1 study to evaluate the safety and tolerability of JNJ-61610588 in adults	12	NCT02671955	Janssen Research & Development, LLC	USA	Terminated
CI-8993	Fully human IgG1ĸ Anti-VISTA mAb	Advanced solid tumors (non-lymphoma)	A multi-center, open-label, Phase 1 dose-escalation study to determine the maximum tolerated dose of CI-8993 in adult patients	16	NCT04475523	Curis, Inc.	USA	Recruiting
CA-170	VISTA/PD-L1/ PD-L2 antagonist	Advanced solid tumors or lymphoma	A multi-center, open-label, Phase 1 study of orally administered CA-170 in adult patients	71	NCT02812875	Curis, Inc.	USA	Completed
HMBD-002	Fc-independent IgG4 Anti-VISTA mAb	Advanced solid tumors	A multi-center, open-label, first-in-human, Phase 1/2 study evaluating multiple doses of HMBD-002, with or without pembrolizumab, in adult patients with solid tumors	Unknown	NCT05082610	Hummingbird Bio, Inc.	USA	Recruiting
W0180	Anti-VISTA mAb	Locally advanced or metastatic solid tumors	A multi-center, open-label, first-in-human, Phase 1 dose escalation and dose expansion study evaluating W0180 as a monotherapy and in combination with pembrolizumab in adults with locally advanced or metastatic solid tumors	Unknown	NCT04564417	Pierre-Fabre	France/Spain	Active, not recruiting
KVA12123 (KVA12.1)	Fully human IgG1 Anti-VISTA mAb	Advanced solid tumors	Kineta is planning to conduct a Phase 1/2 study evaluating KVA12123 as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors	NA	NA	Kineta, Inc.	USA	Planned

IgG, immunoglobulin; mAb, monoclonal antibody; NA, not applicable; PD-L, programmed death-ligand; VISTA, V-domain immunoglobulin suppressor of T cell activation.